Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1606517rdf:typepubmed:Citationlld:pubmed
pubmed-article:1606517lifeskim:mentionsumls-concept:C0021051lld:lifeskim
pubmed-article:1606517lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1606517lifeskim:mentionsumls-concept:C0305052lld:lifeskim
pubmed-article:1606517lifeskim:mentionsumls-concept:C0279033lld:lifeskim
pubmed-article:1606517lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:1606517lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:1606517lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:1606517pubmed:issue1-2lld:pubmed
pubmed-article:1606517pubmed:dateCreated1992-7-23lld:pubmed
pubmed-article:1606517pubmed:abstractTextIVIG is the definitive therapy for primary immunodeficiency diseases associated with hypogammaglobulinemia or specific antibody deficiencies. Administration of IVIG is relatively safe, but occasional adverse reactions are usually self-limited and generally are not an indication for stopping therapy. Home administration of IVIG has found increasing favor among treating physicians and their patients.lld:pubmed
pubmed-article:1606517pubmed:languageenglld:pubmed
pubmed-article:1606517pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1606517pubmed:citationSubsetIMlld:pubmed
pubmed-article:1606517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1606517pubmed:statusMEDLINElld:pubmed
pubmed-article:1606517pubmed:issn0731-8235lld:pubmed
pubmed-article:1606517pubmed:authorpubmed-author:SchwartzS ASAlld:pubmed
pubmed-article:1606517pubmed:issnTypePrintlld:pubmed
pubmed-article:1606517pubmed:volume10lld:pubmed
pubmed-article:1606517pubmed:ownerNLMlld:pubmed
pubmed-article:1606517pubmed:authorsCompleteYlld:pubmed
pubmed-article:1606517pubmed:pagination1-12lld:pubmed
pubmed-article:1606517pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:meshHeadingpubmed-meshheading:1606517-...lld:pubmed
pubmed-article:1606517pubmed:articleTitleClinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.lld:pubmed
pubmed-article:1606517pubmed:affiliationDepartment of Pediatrics, University of Michigan, Ann Arbor 48109-2029.lld:pubmed
pubmed-article:1606517pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1606517pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1606517lld:pubmed